Baxter International Inc. vs Johnson & Johnson
BAX vs JNJ — side-by-side comparison from reported financials. BAX leads 1, JNJ leads 9 of 10 comparable metrics.
Baxter International Inc.
BAX · Healthcare
$24.35+1.88%Mixed
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
| Metric | BAX | JNJ |
|---|---|---|
| Price | $24.35 | $261.79 |
| Market cap | $12.6B | $631B |
| Revenue (TTM) | $11.5B | $97.9B |
| Revenue growth | -9.4% | +5.6% |
| Net margin | -9.3% | 21.5% |
| Free cash flow | $931M | $22.2B |
| Net cash (debt) | $1.97B | ($27.8B) |
| 1-year price return | +8.2% | +37.0% |
| P/E | — | 29.9 |
| P/E vs own history (cheap-side %) | 9% | 16% |
| Dividend yield | 1.46% | 2.00% |
| Return on equity | -17% | 26% |
| Altman Z-score | 2.12 | — |
| CV checks passed | 8 of 10 | 10 of 10 |
| Employees | 37,500 | 140,800 |
Full résumé-style profiles: BAX CV · JNJ CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.